HR 383

To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

Congress: 118 (2023–2025, Ended)
Chamber: House
Policy Area: Health
Introduced: Jan 17, 2023
Current Status: Referred to the Subcommittee on Health.
Latest Action: Referred to the Subcommittee on Health. (Jan 27, 2023)
Official Text: https://www.congress.gov/bill/118th-congress/house-bill/383

Sponsor

Name: Rep. Harshbarger, Diana [R-TN-1]
Party: Republican • **State:** TN • **Chamber:** House

Cosponsors (26 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Baird, James R. [R-IN-4]	R · IN		Jan 17, 2023
Rep. Banks, Jim [R-IN-3]	R · IN		Jan 17, 2023
Rep. Carter, Earl L. "Buddy" [R-GA-1]	R · GA		Jan 17, 2023
Rep. Duncan, Jeff [R-SC-3]	R · SC		Jan 17, 2023
Rep. Feenstra, Randy [R-IA-4]	R · IA		Jan 17, 2023
Rep. Gosar, Paul A. [R-AZ-9]	R · AZ		Jan 17, 2023
Rep. Hern, Kevin [R-OK-1]	R · OK		Jan 17, 2023
Rep. Jackson, Ronny [R-TX-13]	R · TX		Jan 17, 2023
Rep. Lamborn, Doug [R-CO-5]	R · CO		Jan 17, 2023
Rep. Miller, Mary E. [R-IL-15]	R · IL		Jan 17, 2023
Rep. Smith, Christopher H. [R-NJ-4]	R · NJ		Jan 17, 2023
Rep. Weber, Randy K., Sr. [R-TX-14]	R · TX		Jan 17, 2023
Rep. Webster, Daniel [R-FL-11]	R · FL		Jan 17, 2023
Rep. Boebert, Lauren [R-CO-3]	R · CO		Jan 24, 2023
Rep. Flood, Mike [R-NE-1]	R · NE		Jan 24, 2023
Rep. Grothman, Glenn [R-WI-6]	R · WI		Jan 24, 2023
Rep. Moolenaar, John R. [R-MI-2]	R · MI		Jan 24, 2023
Rep. Sessions, Pete [R-TX-17]	R · TX		Jan 24, 2023
Rep. Bost, Mike [R-IL-12]	R · IL		Jan 26, 2023
Rep. Gonzales, Tony [R-TX-23]	R · TX		Jan 26, 2023
Rep. Mast, Brian J. [R-FL-21]	R · FL		Jan 26, 2023
Rep. Yakym, Rudy [R-IN-2]	R · IN		Jan 26, 2023
Rep. Guest, Michael [R-MS-3]	R · MS		Feb 6, 2023
Rep. Luna, Anna Paulina [R-FL-13]	R · FL		Mar 8, 2023
Rep. Higgins, Clay [R-LA-3]	R · LA		Mar 17, 2023
Rep. Aderholt, Robert B. [R-AL-4]	R · AL		Aug 11, 2023

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jan 27, 2023

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
118 HR 4368	Related bill	**Sep 28, 2023:** Motion to reconsider laid on the table Agreed to without objection.

Summary (as of Jan 17, 2023)

This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.)

The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions.

In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers.

The bill nullifies the January 2023 changes and prohibits any similar changes in the future.

Actions Timeline

- **Jan 27, 2023:** Referred to the Subcommittee on Health.
- **Jan 17, 2023:** Introduced in House
- **Jan 17, 2023:** Referred to the House Committee on Energy and Commerce.